InsiderSignal.AI

InsiderSignal.ai

GILD - Gilead Sciences, Inc.

Insider Sale by O'Day Daniel Patrick (COB, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, O'Day Daniel Patrick, serving as COB, CEO at Gilead Sciences, Inc. (GILD), sold 10,000 shares at $136.82 per share, for a total transaction value of $1,368,162.00. Following this transaction, O'Day Daniel Patrick now holds 642,567 shares of GILD.

This sale represents a 2.00% decrease in O'Day Daniel Patrick's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, March 27, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 30, 2026, 3 days after the trade was made.

Gilead Sciences, Inc. operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - GENERAL industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

O'Day Daniel Patrick

COB, CEO

Daniel Patrick O'Day is the Chairman and Chief Executive Officer (CEO) of Gilead Sciences, Inc. (GILD), a position he has held since joining the company in March 2019.[[1]](https://theorg.com/org/gilead-sciences/org-chart/daniel-oday)[[2]](https://www.gurufocus.com/insider/166303/daniel-patrick-o'day) As a corporate insider, he recently sold 10,000 shares of GILD stock on December 29, 2025, at $124.83 per share, reducing his direct ownership to approximately 566,698 shares valued at over $70 million.[[2]](https://www.gurufocus.com/insider/166303/daniel-patrick-o'day)[[3]](https://www.ainvest.com/news/gilead-sciences-ceo-day-sells-10-000-shares-124-83-share-2512/)[[4]](https://www.marketbeat.com/instant-alerts/daniel-patrick-oday-sells-10000-shares-of-gilead-sciences-nasdaqgild-stock-2025-12-30/) O'Day owns about 620,268 shares as reported in mid-2025, with an estimated net worth tied to these holdings exceeding $66 million.[[2]](https://www.gurufocus.com/insider/166303/daniel-patrick-o'day) Prior to Gilead, O'Day spent over three decades at Roche, culminating as CEO of Roche Pharmaceuticals, where he held executive roles across pharmaceutical and diagnostics divisions in North America, Europe, and Asia, and served on Roche's Corporate Executive Committee and boards including Genentech, Flatiron Health, and Foundation Medicine.[[1]](https://theorg.com/org/gilead-sciences/org-chart/daniel-oday) He holds a bachelor's degree in biology from Georgetown University and an MBA from Columbia University.[[1]](https://theorg.com/org/gilead-sciences/org-chart/daniel-oday) O'Day currently serves on the boards of the Pharmaceutical Research and Manufacturers of America (PhRMA) and Galapagos NV, and has led key initiatives at Gilead such as the $21 billion acquisition of Immunomedics to expand oncology offerings.[[1]](https://theorg.com/org/gilead-sciences/org-chart/daniel-oday)[[5]](https://www.youtube.com/watch?v=2WOZmgrmEX8)

View full insider profile →

Trade Price

$136.82

Quantity

10,000

Total Value

$1,368,162.00

Shares Owned

642,567

Trade Date

Friday, March 27, 2026

9 days ago

SEC Filing Date

Monday, March 30, 2026

Filed 3 days after trade

HEALTHCAREDRUG MANUFACTURERS - GENERAL

About Gilead Sciences, Inc.

Company Overview

No company information available
View news mentioning GILD

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5228757

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime